Gene therapy aims to halt blindness from rare crystalline eye disease
NCT ID NCT06699108
First seen Jan 10, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tests a new treatment called VGR-R01 for people with Bietti Crystalline Dystrophy, a rare inherited eye disease that leads to vision loss. The trial involves 45 adults who will receive the treatment or be in a control group. The main goal is to see if the treatment improves or stabilizes eyesight over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED RETINAL DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Vitalgen Biopharma Co.,Ltd.
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.